hif2alpha inhibitor dff332
Generic: HIF2alpha Inhibitor DFF332
hif2alpha inhibitor dff332: 1 clinical trial tracked.
hif2alpha inhibitor dff332 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about hif2alpha inhibitor dff332, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trials (1)
A Phase I/Ib, Open-label, Multi-center Study of DFF332 as a Single Agent and in Combination With Everolimus or IO Agents in Patients With Advanced/Relapsed ccRCC and Other Malignancies With HIF2α Stabilizing Mutations
Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Interventionalopen40 targetStarted 2021-11Completion 2026-0211 sites · Czechia, France, Italy, Japan…Novartis Pharmaceuticals